ArticleActa neuropathologica2024
The prevalence and topography of spinal cord demyelination in multiple sclerosis: a retrospective study.
Article in Acta neuropathologica, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.
- Spinal cord imaging in multiple sclerosis: A vital component we can no longer overlook.Multiple sclerosis (Houndmills, Basingstoke, England) · 2026Pooled it
- Quantitative Susceptibility Mapping of the Cervical Spinal Cord at 3T and Application to Multiple Sclerosis.NMR in biomedicine · 2026Article
- Article
- Association Between Motor Pathway Damage and Motor Deficit in Upper and Lower Limb in People With MS.Annals of clinical and translational neurology · 2026Article
- Generalizable spinal cord multiple sclerosis lesion segmentation across MRI contrasts, protocols, and centers.Multiple sclerosis (Houndmills, Basingstoke, England) · 2026Article
- When is the Radiologically Isolated Syndrome already Multiple Sclerosis According to the 2024 McDonald Criteria?Current neurology and neuroscience reports · 2026Review
- A cause and protective treatment for acute and progressive disability and grey matter atrophy.Brain : a journal of neurology · 2026Review
- Topographical Variation of Iron-Rimmed Lesions in the Multiple Sclerosis Brain and Spinal Cord: A Neuropathological Study.Annals of neurology · 2026Article
- Motor tract lesion mapping from the brain to the lower spinal cord in people with relapsing-remitting multiple sclerosis: exploring the association between lesion severity and functional consequences by limb.Brain communications · 2026Article
- Unveiling a silent threat: slowly expanding spinal cord lesion linked to clinical worsening in multiple sclerosis: a case report.Journal of neurology · 2025Article
- Recent developments in multiple sclerosis neuropathology.Current opinion in neurology · 2025Review
- Multiple Sclerosis-Specific Reference Curves for Brain Volumes to Explain Disease Severity.Neurology · 2025Observational
- Automatic segmentation of spinal cord lesions in MS: A robust tool for axial T2-weighted MRI scans.Imaging neuroscience (Cambridge, Mass.) · 2025Article
- Imaging chronic active lesions in multiple sclerosis: a consensus statement.Brain : a journal of neurology · 2024Review
- Spinal cord evaluation in multiple sclerosis: clinical and radiological associations, present and future.Brain communications · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 3 countries.
Funding
Abstract
Spinal cord pathology is a major determinant of irreversible disability in progressive multiple sclerosis. The demyelinated lesion is a cardinal feature. The well-characterised anatomy of the spinal cord and new analytic approaches allows the systematic study of lesion topography and its extent of inflammatory activity unveiling new insights into disease pathogenesis. We studied cervical, thoracic, and lumbar spinal cord tissue from 119 pathologically confirmed multiple sclerosis cases. Immunohistochemistry was used to detect demyelination (PLP) and classify lesional inflammatory activity (CD68). Prevalence and distribution of demyelination, staged by lesion activity, was determined and topographical maps were created to identify patterns of lesion prevalence and distribution using mixed models and permutation-based voxelwise analysis. 460 lesions were observed throughout the spinal cord with 76.5% of cases demonstrating at least 1 lesion. The cervical level was preferentially affected by lesions. 58.3% of lesions were inflammatory with 87.9% of cases harbouring at least 1 inflammatory lesion. Topographically, lesions consistently affected the dorsal and lateral columns with relative sparing of subpial areas in a distribution mirroring the vascular network. The presence of spinal cord lesions and the proportion of active lesions related strongly with clinical disease milestones, including time from onset to wheelchair and onset to death. We demonstrate that spinal cord demyelination is common, highly inflammatory, has a predilection for the cervical level, and relates to clinical disability. The topography of lesions in the dorsal and lateral columns and relative sparing of subpial areas points to a role of the vasculature in lesion pathogenesis, suggesting short-range cell infiltration from the blood and signaling molecules circulating in the perivascular space incite lesion development. These findings challenge the notion that end-stage progressive multiple sclerosis is 'burnt out' and an outside-in lesional gradient predominates in the spinal cord. Taken together, this study provides support for long-term targeting of inflammatory demyelination in the spinal cord and nominates vascular dysfunction as a potential target for new therapeutic approaches to limit irreversible disability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.